Another clinical trial has been forced to a standstill as biotech firm Sophiris revealed that a patient death had prompted it to put the brakes on its Phase 2b investigation into the efficacy of its pore-forming protein topsalysin in the treatment of prostate cancer.
The death was said to occur on the same day as the patient’s second administration of the therapy, and Sophiris, upon hearing the unfortunate news, halted the administration of any further second doses. Details of what caused the death were not revealed.
Original Article: Sophiris halts cancer study after patient death